Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
F	O
Service:	O
SURGERY	O
Allergies:	O
Penicillins	O
Attending:	O
___.	O
Chief	O
Complaint:	O
Klatskin's	O
tumor	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
___:	O
Left	O
and	O
Right	O
PTB	O
internal/external	O
drains	O
placed	O
with	O
brushings	O
and	O
forceps	O
biopsy	O
___:	O
Drains	O
unclogged	O
due	O
to	O
distal	O
occlusion	O
___:	O
EBUS	O
___:	O
ERCP,	O
previous	O
stent	O
removal	O
and	O
drain	O
upsize	O
___:	O
Cholangiogram,	O
8x60	O
mm	O
metal	O
wall	O
stents	O
to	O
left	O
and	O
right	O
central	O
biliary	O
ducts,	O
10x42	O
mm	O
extending	O
stents	O
placed,	O
Amplatz	O
anchor	O
drains	O
placed.	O
2	O
Gold	O
fiducials	O
in	O
bilateral	O
duct	O
strictures	O
(4	O
markers	O
in	O
all	O
placed)	O
Brushing	O
and	O
Biopsy	O
of	O
left	O
central	O
bile	O
duct	O
stricture	O
___:	O
Anchor	O
drains	O
removed	O
History	O
of	O
Present	O
Illness:	O
Mrs.	O
___	O
is	O
a	O
___	O
female	O
from	O
___	O
with	O
a	O
newly	O
diagnosed	O
Klatskin's	O
tumor.	O
She	O
was	O
found	O
to	O
have	O
a	O
mid-proximal	O
CBD	O
stricture	O
with	O
failed	O
stending	O
in	O
___.	O
She	O
initially	O
presented	O
with	O
abdominal	O
pain	O
and	O
fevers.	O
MRI	O
at	O
that	O
time	O
also	O
showed	O
intrahepatic	O
biliary	O
dilitation	O
with	O
confluence	O
of	O
the	O
right	O
and	O
left	O
hepatic	O
ducts.	O
She	O
was	O
admitted	O
to	O
the	O
hospital	O
and	O
started	O
on	O
broad	O
spectrum	O
antibiotics.	O
She	O
underwent	O
attempted	O
PTC	O
drainage	O
and	O
the	O
intrahepatic	O
duct	O
of	O
the	O
right	O
lobe	O
was	O
punctured.	O
Cholangiogram	O
revealed	O
mild	O
dilitation	O
of	O
the	O
intrahepatic	O
bile	O
ducts.	O
A	O
stricture	O
was	O
seen	O
at	O
the	O
proximal	O
CHD	O
and	O
distal	O
right	O
and	O
left	O
ducts	O
and	O
a	O
plastic	O
stent	O
was	O
placed	O
across	O
the	O
CBD.	O
Afterwards	O
her	O
LFTs	O
downtrended	O
and	O
she	O
was	O
discharged	O
home	O
on	O
antibiotics.	O
Her	O
son	O
contacted	O
Dr.	O
___	O
and	O
she	O
was	O
seen	O
in	O
clinic	O
today	O
after	O
flying	O
over	O
from	O
___.	O
She	O
is	O
feeling	O
well	O
but	O
anxious	O
about	O
having	O
more	O
procedures	O
done.	O
Past	O
Medical	O
History:	O
lung	O
cancer	O
s/p	O
resection/chemotherapy/radiation	O
(___),	O
severe	O
TR,	O
acute	O
kidney	O
injury,	O
hypertension	O
PSH:	O
left	O
lower	O
lobe	O
lung	O
resection	O
(___),	O
hysterectomy	O
Social	O
History:	O
___	O
Family	O
History:	O
Non-contributory	O
Physical	O
Exam:	O
Vital	O
Signs	O
sheet	O
entries	O
for	O
___:	O
BP:	O
135/97.	O
Heart	O
Rate:	O
99.	O
Weight:	O
129	O
(With	O
Clothes;	O
With	O
Shoes).	O
Temperature:	O
98.3.	O
Resp.	O
Rate:	O
18.	O
NAD/AAO,	O
not	O
jaundiced	O
RRR	O
CTA	O
b/l	O
soft,	O
nondistended,	O
nontender	O
no	O
peripheral	O
edema	O
Pertinent	O
Results:	O
On	O
Admission:	O
___	O
WBC-11.4*	O
RBC-4.04*	O
Hgb-11.0*	O
Hct-32.9*	O
MCV-82	O
MCH-27.4	O
MCHC-33.6	O
RDW-18.0*	O
Plt	O
___	O
PTT-34.7	O
___	O
Glucose-158*	O
UreaN-13	O
Creat-1.0	O
Na-129*	O
K-3.2*	O
Cl-98	O
HCO3-24	O
AnGap-10	O
ALT-20	O
AST-33	O
AlkPhos-270*	O
TotBili-0.9	O
Albumin-3.1*	O
Calcium-8.0*	O
Phos-3.0	O
Mg-1.4*	O
___	O
01:35PM	O
BLOOD	O
CEA-1.1	O
AFP-3.6	O
___	O
HBsAg-NEGATIVE	O
HBcAb-NEGATIVE	O
HAV	O
Ab-POSITIVE	O
HCV	O
Ab-NEGATIVE	O
___	O
CA	O
___	O
-32	O
.	O
___:	O
CT	O
Abdomen:	O
1.	O
Poorly	O
defined	O
intrahepatic	O
mass	O
at	O
the	O
ductal	O
confluence,	O
extending	O
above	O
the	O
bifurcation	O
of	O
the	O
right	O
hepatic	O
duct,	O
and	O
just	O
below	O
the	O
bifurcation	O
of	O
the	O
left	O
hepatic	O
duct.	O
It	O
is	O
not	O
certain	O
if	O
this	O
represents	O
Bismuth	O
3	O
or	O
4	O
disease	O
(the	O
latter	O
if	O
the	O
left	O
hepatic	O
duct	O
confluence	O
is	O
involved).There	O
is	O
moderate	O
associated	O
biliary	O
diliation.	O
2.	O
Subcapsular	O
fluid	O
collection	O
along	O
the	O
right	O
lobe	O
of	O
the	O
liver	O
with	O
overlying	O
capsular	O
enhancement,	O
likely	O
related	O
to	O
recent	O
PTC,	O
with	O
associated	O
hematoma	O
or	O
reaction	O
to	O
minor	O
leakage	O
of	O
bile.	O
.	O
CT	O
Chest:	O
Multiple	O
enlarged	O
central	O
lymph	O
nodes,	O
suspicious	O
for	O
lymphatic	O
spread	O
of	O
primary	O
lesion.	O
2.	O
There	O
are	O
no	O
lung	O
nodules	O
suspicious	O
for	O
metastasis.	O
Dependent	O
atelectasis	O
mainly	O
in	O
the	O
lower	O
lobes	O
and	O
lingula.	O
.	O
___:	O
Specimen(s)	O
Submitted:	O
COMMON	O
BILE	O
DUCT	O
BRUSHINGS,	O
from	O
___	O
Common	O
Bile	O
Duct	O
Brushings:	O
NEGATIVE	O
FOR	O
MALIGNANT	O
CELLS.	O
Unremarkable	O
and	O
reactive	O
ductal	O
cells.	O
.	O
___:	O
Right	O
hepatic	O
duct	O
stricture,	O
biopsy:	O
A.	O
Markedly	O
distorted	O
tissue	O
with	O
no	O
evaluable	O
epithelial	O
lining;	O
no	O
carcinoma	O
seen.	O
B.	O
Immunosain	O
for	O
Keratin	O
AE1/AE3/CAM5.2	O
has	O
been	O
evaluated.	O
C.	O
Multiple	O
levels	O
examined.	O
.	O
___:	O
Fine	O
Needle	O
Aspirate	O
(EBUS)	O
Negative	O
for	O
carcinoma	O
.	O
___:	O
ERCP:	O
The	O
left	O
percutaneous	O
transhepatic	O
wire	O
was	O
used	O
to	O
advance	O
the	O
Spyglass	O
catheter	O
into	O
the	O
bile	O
duct	O
to	O
the	O
level	O
of	O
the	O
hilar	O
stricture.	O
The	O
Spyglass	O
catheter	O
could	O
not	O
be	O
advanced	O
into	O
the	O
left	O
hepatic	O
duct	O
to	O
evaluate	O
the	O
extent	O
of	O
disease	O
in	O
this	O
system.	O
The	O
Spyglass	O
catheter	O
was	O
then	O
exchanged	O
over	O
a	O
wire	O
for	O
the	O
pediatric	O
gastroscope,	O
however	O
this	O
also	O
could	O
not	O
be	O
advanced	O
into	O
the	O
left	O
hepatic	O
duct.	O
Therefore	O
the	O
pediatric	O
gastroscope	O
was	O
exchanged	O
for	O
the	O
Spyglass	O
fiber,	O
which	O
was	O
advanced	O
into	O
the	O
left	O
hepatic	O
duct	O
to	O
complete	O
the	O
evaluation.	O
The	O
Spyglass	O
fiber	O
was	O
advanced	O
into	O
the	O
left	O
hepatic	O
duct	O
above	O
the	O
level	O
of	O
the	O
stricture.	O
Contrast	O
was	O
injected	O
to	O
define	O
the	O
left	O
hepatic	O
system.	O
The	O
left	O
intrahepatic	O
ducts	O
appeared	O
normal.	O
The	O
upper	O
edge	O
of	O
the	O
hilar	O
stricture	O
was	O
identified	O
in	O
the	O
left	O
hepatic	O
duct.	O
Under	O
direct	O
Spyglass	O
cholagioscopy	O
and	O
fluoroscopy	O
this	O
appeared	O
to	O
extend	O
1	O
cm	O
into	O
the	O
left	O
hepatic	O
duct.	O
The	O
duct	O
walls	O
above	O
this	O
level	O
appeared	O
normal,	O
while	O
the	O
stricture	O
itself	O
appeared	O
malignant.	O
.	O
___:	O
Left	O
Hepatic	O
duct	O
brushings:	O
ATYPICAL.	O
Sheets	O
of	O
glandular	O
cells	O
with	O
slight	O
crowding	O
and	O
nuclear	O
enlargement.	O
.	O
___:	O
Liver	O
Biopsy:	O
Pending	O
.	O
Culture	O
Data:	O
___:	O
Blood	O
Culture	O
ENTEROCOCCUS	O
FAECIUM	O
AMPICILLIN------------	O
=>32	O
R	O
DAPTOMYCIN------------	O
S	O
LINEZOLID-------------	O
2	O
S	O
PENICILLIN	O
G----------	O
=>64	O
R	O
VANCOMYCIN------------	O
=>32	O
R	O
.	O
___:	O
1+	O
(<1	O
per	O
1000X	O
FIELD):	O
POLYMORPHONUCLEAR	O
LEUKOCYTES.	O
2+	O
___	O
per	O
1000X	O
FIELD):	O
Gram	O
Positive	O
Cocci	O
IN	O
PAIRS.	O
1+	O
(<1	O
per	O
1000X	O
FIELD):	O
GRAM	O
POSITIVE	O
ROD(S).	O
1+	O
(<1	O
per	O
1000X	O
FIELD):	O
BUDDING	O
YEAST.	O
Blood	O
Cultures	O
___	O
No	O
Growth	O
Labs	O
at	O
Discharge:	O
___	O
WBC-8.2	O
RBC-3.71*	O
Hgb-10.2*	O
Hct-33.2*	O
MCV-90	O
MCH-27.4	O
MCHC-30.6*	O
RDW-18.0*	O
Plt	O
___	O
PTT-45.4*	O
___	O
Glucose-125*	O
UreaN-10	O
Creat-0.9	O
Na-136	O
K-3.8	O
Cl-98	O
HCO3-26	O
AnGap-16	O
ALT-52*	O
AST-57*	O
AlkPhos-520*	O
TotBili-0.6	O
Calcium-9.0	O
Phos-2.4*	O
Mg-1.___	O
y/o	O
female	O
who	O
has	O
travelled	O
from	O
___	O
for	O
further	O
evaluation	O
of	O
Klatskin	O
tumor.	O
Initially,	O
she	O
underwent	O
CTA	O
of	O
the	O
abdomen	O
with	O
findings	O
concerning	O
for	O
moderate	O
right	O
intrahepatic	O
biliary	O
dilatation	O
and	O
mild-moderate	O
left	O
lateral	O
segmental	O
biliary	O
dilation.	O
Poorly	O
defined	O
intrahepatic	O
tumor	O
mass	O
was	O
seen	O
at	O
the	O
confluence	O
of	O
the	O
right	O
and	O
left	O
hepatic	O
ducts,	O
with	O
the	O
common	O
hepatic	O
duct.	O
On	O
___,	O
she	O
had	O
left	O
and	O
right	O
PTB	O
internal/external	O
drains	O
placed	O
with	O
brushings	O
and	O
forceps	O
biopsy	O
done.	O
That	O
biopsy	O
did	O
not	O
show	O
carcinoma,	O
and	O
the	O
brushings	O
were	O
negative	O
for	O
malignant	O
cells.	O
Following	O
the	O
drain	O
placement	O
she	O
was	O
started	O
on	O
Ciprofloxacin	O
500	O
mg	O
BID.	O
The	O
initial	O
specimens	O
from	O
this	O
procedure	O
were	O
also	O
cultured,	O
and	O
did	O
not	O
grow	O
any	O
bacteria.	O
On	O
___,	O
she	O
developed	O
fever	O
to	O
102.3	O
and	O
was	O
sent	O
to	O
interventional	O
radiology	O
for	O
drain	O
evaluation.	O
Distal	O
occlusion	O
was	O
noted	O
and	O
the	O
drains	O
were	O
un-clogged.	O
Cipro	O
was	O
switched	O
to	O
broad	O
coverage	O
with	O
Zosyn.	O
She	O
continued	O
to	O
have	O
fevers	O
as	O
high	O
as	O
102.7.	O
Blood	O
and	O
bile	O
cultures	O
were	O
obtained	O
at	O
that	O
time,	O
and	O
Vancomycin	O
was	O
added	O
for	O
gram	O
positive	O
coverage.	O
However,	O
when	O
the	O
culture	O
data	O
finalized	O
as	O
Vancomycin	O
resistant	O
Enterococci,	O
Vancomycin	O
was	O
switched	O
to	O
Daptomycin.	O
Bile	O
culture	O
isolated	O
heavy	O
growth	O
yeast,	O
presumptively	O
not	O
C	O
albicans,	O
heavy	O
growth	O
of	O
an	O
Enterococcus	O
species	O
and	O
rare	O
growth	O
of	O
Pseudomonas.	O
Micafungin	O
was	O
added	O
for	O
the	O
yeast	O
coverage.	O
Fevers	O
subsided	O
over	O
the	O
next	O
___	O
hours,	O
and	O
she	O
has	O
remained	O
afebrile	O
since	O
that	O
time.	O
The	O
___	O
service	O
(the	O
pancreatico-biliary	O
service)directed	O
by	O
Dr.	O
___	O
endobronchial	O
ultrasound	O
and	O
biopsy	O
to	O
be	O
done	O
with	O
the	O
pulmonary	O
surgeon	O
due	O
to	O
the	O
multiple	O
enlarged	O
central	O
lymph	O
nodes,	O
suspicious	O
for	O
lymphatic	O
spread	O
of	O
primary	O
lesion	O
as	O
seen	O
on	O
admission	O
chest	O
CT.	O
The	O
procedure	O
(EBUS)was	O
done	O
without	O
complication	O
on	O
___.	O
Pathology	O
was	O
negative	O
for	O
malignancy.	O
On	O
___,	O
an	O
ERCP	O
was	O
done	O
for	O
removal	O
of	O
the	O
previously	O
placed	O
stent	O
which	O
was	O
performed	O
in	O
___.	O
The	O
drains	O
were	O
up	O
sized,	O
and	O
a	O
Spyglass	O
procedure	O
was	O
performed.	O
On	O
___,	O
she	O
underwent	O
a	O
cholangiogram	O
with	O
placement	O
of	O
an	O
8x60	O
mm	O
metal	O
wall	O
stent	O
to	O
the	O
left	O
and	O
right	O
central	O
biliary	O
ducts	O
with	O
additional	O
10x42	O
mm	O
extending	O
stents	O
placed,	O
Amplatz	O
anchor	O
drains	O
were	O
left	O
in	O
place	O
thru	O
the	O
wall	O
stents.	O
Four	O
fiducials	O
were	O
placed,	O
2	O
fiducial	O
markers	O
adjacent	O
to	O
region	O
of	O
left	O
central	O
ductal	O
stricture,	O
one	O
fiducial	O
marker	O
adjacent	O
to	O
region	O
of	O
right	O
central	O
ductal	O
stricture	O
and	O
one	O
fiducial	O
marker	O
in	O
hepatic	O
segment	O
VII.	O
One	O
of	O
the	O
fiducials	O
migrated	O
to	O
the	O
posterior	O
right	O
hepatic	O
lobe	O
during	O
deployment.	O
Internal/external	O
wall	O
stents	O
(anchor	O
drains)	O
were	O
removed	O
the	O
next	O
day.	O
LFTs	O
were	O
notable	O
for	O
slight	O
increase	O
in	O
alk	O
phos	O
post	O
removal	O
with	O
alk	O
phos	O
increased	O
to	O
520	O
from	O
mid	O
___	O
to	O
low	O
400s.	O
She	O
remained	O
afebrile	O
and	O
there	O
was	O
no	O
drainage	O
from	O
the	O
exit	O
sites.	O
Dry	O
dressings	O
were	O
placed.	O
Lidoderm	O
patch	O
was	O
used	O
for	O
pain	O
at	O
drain	O
sites.	O
Infectious	O
disease	O
team	O
was	O
consulted	O
early	O
in	O
the	O
hospitalization,and	O
followed	O
throughout	O
this	O
hospitalization	O
making	O
recommendations	O
for	O
modifying	O
the	O
antibiotic	O
course.	O
Recommendations	O
included	O
completion	O
of	O
the	O
antibiotics	O
48	O
hours	O
after	O
the	O
external	O
drains	O
were	O
pulled.	O
She	O
received	O
3	O
days	O
of	O
Cipro	O
500	O
BID,	O
2	O
days	O
of	O
Vancomycin	O
1	O
gram	O
BID,	O
17	O
days	O
of	O
Daptomycin	O
450	O
mg	O
BID,	O
16	O
days	O
of	O
Micafungin	O
100	O
mg	O
daily,	O
19	O
days	O
of	O
Zosyn	O
4.5	O
mg	O
TID.	O
Surveillance	O
blood	O
cultures	O
were	O
done	O
after	O
the	O
antibiotics	O
were	O
started,	O
and	O
have	O
all	O
been	O
negative.	O
She	O
has	O
remained	O
afebrile	O
with	O
last	O
fever	O
recorded	O
on	O
___.	O
On	O
___,	O
she	O
felt	O
well	O
enough	O
for	O
discharge	O
from	O
the	O
hospital.	O
The	O
plan	O
is	O
to	O
have	O
f/u	O
with	O
radiation	O
oncology	O
for	O
likely	O
cyberknife	O
treatments.	O
She	O
will	O
follow	O
up	O
with	O
Dr.	O
___	O
on	O
___.	O
At	O
time	O
of	O
discharge,	O
vital	O
signs	O
were	O
stable,	O
she	O
alert	O
and	O
oriented,	B-Delirium
tolerating	O
a	O
regular	O
diet	O
and	O
ambulating	B-Mobile_with_assistance
with	B-Mobile_with_assistance
supervision.	B-Mobile_with_assistance
Medications	O
on	O
Admission:	O
The	O
Preadmission	O
Medication	O
list	O
is	O
accurate	O
and	O
complete.	O
1.	O
Amlodipine	O
5	O
mg	O
PO	O
DAILY	O
2.	O
bisoprolol	O
fumarate	O
5	O
mg	O
oral	O
Daily	O
3.	O
Metoclopramide	O
10	O
mg	O
PO	O
TID:PRN	O
nausea	O
4.	O
Acetaminophen	O
500	O
mg	O
PO	O
Q8H:PRN	O
pain	O
5.	O
Citalopram	O
5	O
mg	O
PO	O
DAILY	O
6.	O
esomeprazole	O
magnesium	O
40	O
mg	O
oral	O
Daily	O
Discharge	O
Medications:	O
1.	O
Acetaminophen	O
650	O
mg	O
PO	O
Q6H	O
For	O
pain	O
2.	O
Amlodipine	O
5	O
mg	O
PO	O
DAILY	O
3.	O
OxycoDONE	O
(Immediate	O
Release)	O
___	O
mg	O
PO	O
Q4H:PRN	O
pain	O
RX	O
*oxycodone	O
5	O
mg	O
1	O
capsule(s)	O
by	O
mouth	O
q	O
4	O
hours	O
Disp	O
#*60	O
Tablet	O
Refills:*0	O
4.	O
Esomeprazole	O
Magnesium	O
40	O
mg	O
ORAL	O
DAILY	O
5.	O
bisoprolol	O
fumarate	O
5	O
mg	O
oral	O
Daily	O
6.	O
Citalopram	O
5	O
mg	O
PO	O
DAILY	O
Take	O
___	O
of	O
the	O
10	O
mg	O
tablet	O
7.	O
FoLIC	O
Acid	O
1	O
mg	O
PO	O
DAILY	O
8.	O
Metoclopramide	O
10	O
mg	O
PO	O
TID:PRN	O
nausea	O
RX	O
*metoclopramide	O
HCl	O
10	O
mg	O
10	O
mg	O
by	O
mouth	O
three	O
times	O
a	O
day	O
Disp	O
#*30	O
Tablet	O
Refills:*0	O
9.	O
Enoxaparin	O
Sodium	O
60	O
mg	O
SC	O
ONCE	O
pre	O
flight	O
Duration:	O
1	O
Dose	O
Start:	O
___,	O
First	O
Dose:	O
STAT	O
RX	O
*enoxaparin	O
60	O
mg/0.6	O
mL	O
60	O
mg	O
SC	O
Once	O
Disp	O
#*1	O
Syringe	O
Refills:*0	O
10.	O
Lidocaine	O
5%	O
Patch	O
1	O
PTCH	O
TD	O
DAILY	O
Discharge	O
Disposition:	O
Home	O
Discharge	O
Diagnosis:	O
Suspected	O
Klatskins	O
tumor	O
Biliary	O
stricture	O
Metal	O
wall	O
stents	O
placed	O
VRE	O
Bacteremia	O
___	O
Discharge	O
Condition:	O
Mental	O
Status:	O
Clear	B-Delirium
and	B-Delirium
coherent.	B-Delirium
Level	O
of	O
Consciousness:	O
Alert	O
and	O
interactive.	O
Activity	O
Status:	O
Ambulatory	B-Independently_mobile
-	B-Independently_mobile
Independent.	B-Independently_mobile
Discharge	O
Instructions:	O
Please	O
call	O
Dr.	O
___	O
office	O
at	O
___	O
for	O
fever	O
>	O
101,	O
chills,	O
nausea,	O
vomiting,	O
diarrhea,	O
constipation,	B-Constipation
increased	O
abdominal	O
pain,	O
pain	O
not	O
controlled	O
by	O
your	O
pain	O
medication,	O
swelling	O
of	O
the	O
abdomen	O
or	O
ankles,	O
yellowing	O
of	O
the	O
skin	O
or	O
eyes,	O
inability	O
to	O
tolerate	O
food,	O
fluids	O
or	O
medications,	O
or	O
drainage	O
from	O
the	O
previous	O
drain	O
sites.	O
You	O
may	O
shower.	O
Pat	O
abdomen	O
dry,	O
do	O
not	O
apply	O
lotions	O
or	O
powders	O
to	O
the	O
incision	O
area..	O
No	O
lifting	O
more	O
than	O
10	O
pounds	O
Followup	O
Instructions:	O
___	O

